| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Eur J Cardiothorac Surg 2003;24:785-793
© 2003 Elsevier Science NL
a Department of Cardiovascular Surgery, University Hospital Freiburg, Freiburg, Germany
b Department of Cardiovascular Surgery, University of Schleswig Holstein, Campus Kiel, School of Medicine, Kiel, Germany
Received 12 December 2002; received in revised form 2 June 2003; accepted 16 June 2003.
* Corresponding author. Department of Cardiovascular Surgery, University of Schleswig Holstein, Campus Kiel, School of Medicine, Arnold-Heller-Str. 7, 24105 Kiel, Germany. Tel.: +49-431-597-4401; fax: +49-431-597-4402
e-mail: lutter{at}kielheart.uni-kiel.de
Objective: Growth factor gene therapy represents one current approach in the therapy of myocardial ischemia. We assessed the in vitro and in vivo expression of naked plasmid DNA aiming at preservation of function in a chronically ischemic myocardial model. Methods: In vitro: Primary cardiac fibroblasts were transfected with plasmids encoding enhanced green fluorescent protein, human VEGF121, human FGF-2, or porcine MCP-1. Protein synthesis was assessed microscopically, by ELISA, Western blotting, or intracellular immunofluorescence. In vivo: A LAD stenosis was created in healthy pigs. One week later, segmental myocardial shortening (SMS) and systemic hemodynamics (left ventricular stroke work index, LVSWI, time derivative of left ventricular pressure, dp/dtmax) were assessed at baseline. Afterwards, the ischemic area received either intramyocardial injections of naked cytokine plasmid DNA or vector only, or was left untreated. One myocardial sample taken 1 h after plasmid injection was subjected to RT-PCR and PCR. After 3 months, cardiac function was re-examined. Results: In vitro: Transfection of cardiac fibroblasts resulted in high gene expression for several days. In vivo: Plasmid-specific DNA and mRNA were found 1 h after plasmid injection (n=1). After 3 months, VEGF, FGF-2, and vector rendered better results of regional contractility at rest and of LVSWI. However, only VEGF and FGF-2 were effective with regard to regional contractility under dobutamine stress and to left ventricular contractility. Conclusion: In conclusion, intramyocardial injection of naked plasmid DNA encoding VEGF121 or FGF-2 improved myocardial function in chronic ischemia in more aspects than vector only and was superior to untreated ischemia or MCP-1. This strategy can be considered a successful tool for growth factor stimulated preservation of function in chronic myocardial ischemia.
Key Words: Growth factors • Gene therapy • Coronary disease • Molecular biology
This article has been cited by other articles:
|
|
 |
|
  O. J. Muller, H. A. Katus, and R. Bekeredjian Targeting the heart with gene therapy-optimized gene delivery methods Cardiovasc Res, February 1, 2007; 73(3): 453 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Choi, K.-B. Kim, W. Han, D. S. Kim, J. S. Park, J. J. Lee, and D. S. Lee Efficacy of Therapeutic Angiogenesis by Intramyocardial Injection of pCK-VEGF165 in Pigs Ann. Thorac. Surg., August 1, 2006; 82(2): 679 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Appoo, C. Norris, S. Merali, M. M. Graham, A. Koshal, M. L. Knudtson, and W. A. Ghali Long-Term Outcome of Isolated Coronary Artery Bypass Surgery in Patients With Severe Left Ventricular Dysfunction Circulation, September 14, 2004; 110(11_suppl_1): II-13 - II-17. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
